Six analysts put Cytek Biosciences stock at USD 5.56
Published on 10/15/2026 at 20:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and earnings date
- MarketBeat reported a USD 5.56 average target from six analysts on October 13, 2026.
- Cytek recorded USD 48.14 million in second-quarter revenue for the period ended June 30, 2026.
- Cytek Biosciences stock costs EUR 4.83 at Lang & Schwarz on October 15, 2026 at 10:10 p.m. CEST.
- Yahoo Finance lists November 4, 2026 as the estimated next earnings date.
Six analysts put Cytek Biosciences stock at an average 12-month target of USD 5.56, according to MarketBeat on October 13, 2026. The target stood 2.21 percent above the Nasdaq quote of USD 5.44 at 2:18 p.m. EDT on October 15, 2026. At Lang & Schwarz, the stock was trading at EUR 4.83 on October 15, 2026 at 10:10 p.m. CEST.
Second-quarter revenue reached USD 48.14 million
Cytek reported revenue of USD 48.14 million for the second quarter ended June 30, 2026, compared with a consensus estimate of USD 47.31 million, according to MarketBeat. The quarter also included a loss of USD 0.09 per share, matching the consensus estimate.
Nasdaq quote stays below the yearly high
The Nasdaq quote of USD 5.44 on October 15, 2026 stood 12.40 percent below the 52-week high of USD 6.21 and 64.05 percent above the low of USD 3.31. Cytek's year-to-date performance was 6.83 percent through October 14, 2026, while volume reached 403,841 shares against an average of 1,114,651.
Valuation and next reporting date
Cytek's market capitalization was USD 706.5 million on October 15, 2026. Yahoo Finance lists November 4, 2026 as the estimated next earnings date.
Comparison with peers
CTKB: plus 0.75 percent, P/E -8.73, market capitalization USD 706.5 million
Standard BioTools (Nasdaq, USD): plus 4.59 percent, P/E -2.87, market capitalization USD 259.5 million
10x Genomics (Nasdaq, USD): minus 2.33 percent, P/E -121.02, market capitalization USD 9.3 billion
Trading continues after the Xetra close
At Lang & Schwarz, Cytek Biosciences stock was trading at EUR 4.83 on October 15, 2026 at 10:10 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Cytek Biosciences stock.
Cytek Biosciences market data
- Company: Cytek Biosciences, Inc.
- ISIN: US23285D1090
- Ticker: CTKB
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 10:10 p.m. CEST): EUR 4.83
- Market capitalization: USD 706.5 million (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
